Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms

Molecular Psychiatry

Volumn 8, Issue 9, 2003, Pages 786-796

  Hol, E M ^a   Roelofs, R F ^a   Moraal, E ^a   Sonnemans, M A F ^a   Sluijs, J A ^a   Proper, E A ^b,c   De Graan, P N E ^b   Fischer, D F ^a   Van Leeuwen, F W ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

Author keywords

Aberrant splicing; Alzheimer's disease; Down syndrome; Glial fibrillary acidic protein; Neurodegenerative disease; Neurofibrillary tangles

Indexed keywords

BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN NERVE CELL; DOWN SYNDROME; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL;

ALTERNATIVE SPLICING; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BASE SEQUENCE; DOWN SYNDROME; EPILEPSY, TEMPORAL LOBE; EXONS; FEMALE; FRAMESHIFTING, RIBOSOMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEUROGLIA; NEURONS; READING FRAMES; RNA, MESSENGER; SCLEROSIS; TRANSCRIPTION, GENETIC;

EID: 0042831059     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001379     Document Type: Article

References (45)

1. Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995; 310: 970-973.
2. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8: 447-453.
3. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996; 2: 783-787.
4. Van Leeuwen FW, De Kleijn DPV, Van den Hurk HH, Neubauer A, Sonnemans MAF, Sluijs JA et al. Frameshift mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-247.
5. Muramori F, Kobayashi K, Nakamura I. A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and non-Alzheimer neuropsychiatric diseases. Psychiatry Clin Neurosci 1998; 52: 593-599.
6. Hanzel DK, Trojanowski JQ, Johnston RF, Loring JF. High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. Nat Biotechnol 1999; 17: 53-57.
7. Beach TG, Walker R, McGeer EG. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 1989; 2: 420-436.
8. Van Leeuwen FW, Burbach JPH, Hol EM. Mutations in RNA: a first example of molecular misreading in Alzheimer's disease. Trends Neurosci 1998; 21: 331-335.
9. Van Leeuwen FW, Fischer DF, Kamel D, Sluijs JA, Sonnemans MAF, Benne R et al. Molecular misreading: a new type of transcript mutation expressed during aging. Neurobiol Aging 2000; 21: 879-891.
10. Hol EM, Neubauer A, De Kleijn DPV, Sluijs JA, Ramdjielal RDJ, Sonnemans MAF et al. Dinucleotide deletions in neuronal transcripts: a novel type of mutation in non-familial Alzheimer's disease and Down syndrome patients. Prog Brain Res 1998; 117: 379-395.
11. Evans DAP, Van der Kleij AAM, Sonnemans MAF, Burbach JPH, Van Leeuwen FW. Frameshift mutations at two hotspots in vasopressin transcripts in post-mitotic neurons. Proc Natl Acad Sci USA 1994; 91: 6059-6063.
12. Brenner M. Structure and transcriptional regulation of the GFAP gene. Brain Pathol 1994; 4: 245-257.
13. Reeves SA, Helman LJ, Allison A, Israel MA. Molecular cloning and primary structure of human glial fibrillary acidic protein. Proc Natl Acad Sci USA 1989; 86: 5178-5182.
14. Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 2001; 27: 117-120.
15. Aoki Y, Haginoya K, Munakata M, Yokoyama H, Nishio T, Togashi N et al. A novel mutation in glial fibrillary acidic protein gene in a patient with Alexander disease. Neurosci Lett 2001; 312: 71-74.
16. Messing A, Goldman JE, Johnson AB, Brenner M. Alexander disease: new insights from genetics. J Neuropathol Exp Neurol 2001; 60: 563-573.
17. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
18. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
19. Dahl D, Bignami A. Immunogenic properties of the glial fibrillary acidic protein. Brain Res 1976; 116: 150-157.
20. Neumann M, Gabel D. Simple method for reduction of autofluorescence in fluorescence microscopy. J Histochem Cytochem 2002; 50: 437-439.
21. Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 1997; 48: 128-132.
22. van Den Hurk WH, Willems HJ, Bloemen M, Martens GJ. Novel frameshift mutations near short simple repeats. J Biol Chem 2001; 276: 11496-11498.
23. Seidl R, Cairns N, Lubec G. The brain in Down syndrome. J Neural Transm Suppl 2001; 61: 247-261.
24. Proper EA, Oestreicher AB, Jansen GH, Veelen CW, van Rijen PC, Gispen WH et al. Immunohistochemical characterization of mossy fibre sprouting in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 2000; 123: 19-30.
25. Bender BL, Yunis EJ. Central nervous system pathology of tuberous sclerosis in children. Ultrastruct Pathol 1980; 1: 287-299.
26. Probst A, Ulrich J, Heitz PU. Senile dementia of Alzheimer type: astroglial reaction to extracellular neurofibrillary tangles in the hippocampus. Acta Neuropathol 1982; 57: 75-79.
27. Yamaguchi H, Morimatsu M, Hirai S, Takahashi K. Alzheimer's neurofibrillary tangles are penetrated by astroglial processes and appear eosinophilic in their final stages. Acta Neuropathol 1987; 72: 214-217.
28. Feinstein DA, Weinmaster GA, Milner R. Isolation of cDNA clones encoding rat glial fibrillary acidic protein: expression in astrocytes and in Schwann cells. J Neurosci Res 1992; 32: 1-14.
29. Zelenika D, Grima B, Brenner M, Pessac B. A novel glial fibrillary acidic protein mRNA lacking exon 1. Brain Res Mol Brain Res 1995; 30: 251-258.
30. Condorelli DF, Nicoletti VG, Barresi V, Conticello SG, Caruso A, Tendi EA et al. Structural features of the rat GFAP gene and identification of a novel alternative transcript. J Neurosci Res 1999; 56: 219-228.
31. Nielsen AL, Holm IE, Johansen M, Bonven BJ, Jorgensen P, Jorgensen AL. A new splice form of glial fibrillary acidic protein, GFAP epsilon, interacts with the presenilin proteins. J Biol Chem 2002; 277: 29983-29991.
32. Mount SM. Genomic sequence, splicing, and gene annotation. Am J Hum Genet 2000; 67: 788-792.
33. Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 1985; 8: 203-214.
34. Gomi H, Yokoyama T, Fujimoto K, Ikeda T, Katoh A, Itoh T et al. Mice devoid of the glial fibrillary acidic protein develop normally and are susceptible to scrapie prions. Neuron 1995; 14: 29-41.
35. Pekny M, Johansson CB, Eliasson C, Stakeberg J, Wallen A, Perlmann T et al. Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin. J Cell Biol 1999; 145: 503-514.
36. Inagaki M, Nakamura Y, Takeda M, Nishimura T, Inagaki N. Glial fibrillary acidic protein: dynamic property and regulation by phosphorylation. Brain Pathol 1994; 4: 239-243.
37. Laywell ED, Rakic P, Kukekov VG, Holland EC, Steindler DA. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci USA 2000; 97: 13883-13888.
38. Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 2000; 289: 1754-1757.
39. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 1997; 150: 1933-1939.
40. Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci 1997; 17: 3588-3598.
41. Dranovsky A, Vincent I, Gregori L, Schwarzman A, Colflesh D, Enghild J et al. Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiol Aging 2001; 22: 517-528.
42. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 2001; 21: 2661-2668.
43. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 9902-9906.
44. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002; 157: 417-427.
45. De Vrij FMS, Sluijs JA, Gregori L, Fischer DF, Hermens WTJMC, Goldgaber D et al. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death. FASEB J 2001; 15: 2680-2688.